TABLE 9.
RIGHT EYES | LEFT EYES | |||
---|---|---|---|---|
OR (95% CI) | PVALUE | OR (95% CI) | PVALUE | |
RISK FACTOR | ||||
Clinically important vitreous organization | 31.41 (5.37, 183.63) | <.0001 | 13.18 (2.97, 58.59) | <.0001 |
Clinically important vitreous hemorrhage | 38.49 (2.69, 551.19) | .007 | 15.41 (1.65, 144.12) | .02 |
Zone I threshold | 80.55 (7.82, 829.63) | <.0001 | 45.71 (5.45, 383.37) | <.0001 |
Active stage 3 disease beyond 21 days | 1.41 (0.003, 622.55) | .91 | 0.54 (0.01, 27.15) | .76 |
Active elements of plus disease beyond 21 days | 11.14 (0.02, 5337.68) | .45 | 7.58 (0.35, 165.80) | .20 |
>5 Clock hours stage 3 disease | 7.39 (0.898, 60.91) | .06 | 1.55 (0.30, 7.94) | .60 |
Zone I threshold and active stage 3 beyond 21 days* | 0.25 (.000011, 52.61) | .34 | 0.33 (0.001, 86.96) | .70 |
OR = odds ratio.
This interaction term was included to account for an interaction that was felt to be an anomaly based on the small number of eyes with this covariate pattern.